Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Cinzia Scavullo, Federica Servida, Daniele Lecis, Francesco Onida, Carmelo Drago, Luca Ferrante, Pierfausto Seneci, Wilma Barcellini, Marta Lionetti, Katia Todoerti, Antonino Neri, Domenico Delia, Giorgio Lambertenghi Deliliers

Research output: Contribution to journalArticlepeer-review


Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.

Original languageEnglish
Pages (from-to)809-815
Number of pages7
JournalLeukemia Research
Issue number7
Publication statusPublished - Jul 2013


  • Apoptosis
  • B-CLL
  • Caspases
  • Smac-mimetics
  • Therapy
  • TNF

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)'. Together they form a unique fingerprint.

Cite this